trial · primary record
tividenofusp alfa
Mucopolysaccharidosis II
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 99 |
| Primary completion | 2027-06 |
| Primary endpoint | Incidence and intensity of treatment-emergent adverse events (TEAEs) |
| Registry ID | NCT06075537 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:14.683Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06075537
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.